A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Anticancer Research

• Publication date

  2010-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 20651376
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A WT1 protein‐derived, naturally processed 16‐mer peptide, WT1332, is a promiscuous helper peptide for induction of WT1‐specific Th1‐type CD4+ T cells

  2008cited by this paper
• WT1 (Wilms' Tumor 1) Peptide Immunotherapy for Renal Cell Carcinoma

  2007cited by this paper
• Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma

  2007cited by this paper
• Clinical and Immunologic Responses to Very Low-Dose Vaccination with WT1 Peptide (5 µg/Body) in a Patient with Chronic Myelomonocytic Leukemia

  2007cited by this paper
• Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape.

  2007cited by this paper
• Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia.

  2007cited by this paper
• Identification and Characterization of a WT1 (Wilms Tumor Gene) Protein-derived HLA-DRB1*0405-restricted 16-mer Helper Peptide That Promotes the Induction and Activation of WT1-specific Cytotoxic T Lymphocytes

  2007cited by this paper
• WT1 Peptide Cancer Vaccine for Patients with Hematopoietic Malignancies and Solid Cancers

  2007cited by this paper
• Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway

  2006cited by this paper
• Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

  2005cited by this paper
• T-Cell Responses Directed against Multiple HLA-A*0201-Restricted Epitopes Derived from Wilms' Tumor 1 Protein in Patients with Leukemia and Healthy Donors: Identification, Quantification, and Characterization

  2005cited by this paper
• Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma

  2004cited by this paper
• WT1 Peptide‐Based Immunotherapy for Patients with Lung Cancer: Report of Two Cases

  2004cited by this paper
• Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.

  2004cited by this paper
• Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory

  2003cited by this paper
• Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo.

  2003cited by this paper
• CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

  2003cited by this paper
• The complex role of interleukin-10 in autoimmunity.

  2003cited by this paper
• Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues

  2002cited by this paper
• Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness

  2001cited by this paper
• HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.

  2000cited by this paper
• Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens.

  1999cited by this paper
• IL-10 impacts autoimmune diabetes via a CD8+ T cell pathway circumventing the requirement for CD4+ T and B lymphocytes.

  1998cited by this paper
• T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions

  1998cited by this paper
• The Wilms' tumor 1 gene: oncogene or tumor suppressor gene?

  1998cited by this paper
• IL‐10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages

  1998cited by this paper
• Help for cytotoxic-T-cell responses is mediated by CD40 signalling

  1998cited by this paper
• Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia.

  1997cited by this paper
• A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice.

  1997cited by this paper
• Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes.

  1996cited by this paper
• Interleukin 10 protects activated human T lymphocytes against growth factor withdrawal-induced cell death but only anti-fas antibody can prevent activation-induced cell death.

  1996cited by this paper
• A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines.

  1996cited by this paper
• Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory.

  1995cited by this paper
• In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation.

  1995cited by this paper
• Structural and functional characterization of two wheat histone H2B promoters

  1995cited by this paper
• WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.

  1994cited by this paper
• Production of interleukin 10 by islet cells accelerates immune-mediated destruction of beta cells in nonobese diabetic mice

  1994cited by this paper
• WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant.

  1993cited by this paper
• Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration.

  1993cited by this paper
• Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping

  1990cited by this paper
• Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.

  1990cited by this paper

• WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine

  2022cites this paper
• A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies

  2021cites this paper
• Nutrition, Immunity and Viral Infections

  2020cites this paper
• Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides

  2020cites this paper
• Cooperation of Oligodeoxynucleotides and Synthetic Molecules as Enhanced Immune Modulators

  2019cites this paper
• CpG Oligodeoxynucleotides as Adjuvants for Clinical Use

  2017cites this paper
• Induction of eEF2-specific antitumor CTL responses in vivo by vaccination with eEF2-derived 9mer-peptides.

  2016cites this paper
• Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide

  2016cites this paper
• Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.

  2015cites this paper
• Allogeneic and Autologous T cell Strategies to Enhance Targeting of Acute Myeloid Leukemias

  2015cites this paper
• Impact des inhibiteurs de la voie mTOR sur la réponse immunitaire T anti-tumorale

  2015cites this paper
• Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.

  2014cites this paper
• Identification of a Wilms’ tumor 1-derived immunogenic CD4+ T-cell epitope that is recognized in the context of common Caucasian HLA-DR haplotypes

  2013cites this paper
• Functional human Th17 clones with WT1-specific helper activity

  2013cites this paper
• HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T Lymphocytes Display a Helper Activity for WT1-specific CTL Induction and a Cytotoxicity Against Leukemia Cells

  2013cites this paper
• Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.

  2012cites this paper
• Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor

  2012cites this paper
• No Oncogenic Role for WT1 in Peripheral Nerve Sheath Tumors

  2011cites this paper
• Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.

  2011cites this paper